BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target

BTIG analyst Sam Eiber has reiterated a Buy rating on Neuronetics (NASDAQ: STIM) and has maintained a price target of $6 for the stock. This reaffirmation suggests confidence in the company's future performance.